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LAMP2eins act at several crucial steps of the lysosome life cycle, including lumen
acidiﬁcation, metabolite export, molecular motor recruitment and fusion with other organelles. This review
summarizes the molecular mechanisms of lysosomal storage diseases caused by defective transport of small
molecules or ions across the lysosomal membrane, as well as Danon disease. In cystinosis and free sialic acid
storage diseases, transporters for cystine and acidic monosaccharides, respectively, are blocked or retarded. A
putative cobalamin transporter and a hybrid transporter/transferase of acetyl groups are defective in
cobalamin F type disease and mucopolysaccharidosis type IIIC, respectively. In neurodegenerative forms of
osteopetrosis, mutations of a proton/chloride exchanger impair the charge balance required for sustained
proton pumping by the V-type ATPase, thus resulting in bone-resorption lacuna neutralization. However, the
mechanism leading to lysosomal storage and neurodegeneration remains unclear. Mucolipidosis type IV is
caused by mutations of a lysosomal cation channel named TRPML1; its gating properties are still poorly
understood and the ion species linking this channel to lipid storage and membrane trafﬁc defects is debated.
Finally, the autophagy defect of Danon disease apparently arises from a role of LAMP2 in lysosome/
autophagosome fusion, possibly secondary to a role in dynein-based centripetal motility.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionLysosomes are intracellular hydrolytic organelles able to degrade a
wide variety of macromolecules as well as whole damaged organelles.
This potent and versatile degradative power is segregated from other
cell constituents by a phospholipid membrane, which requires
proteins to fulﬁl diverse molecular functions. Lysosomes are acidiﬁed
by a V-type H+-ATPase to promote enzymatic activity and control
biogenesis steps such as the maturation of hydrolytic enzymes [1].
Lysosomal catabolites produced in the lumen are exported to the
cytosol by membrane transporters to allow their reuse in cell
metabolism [2]. These transporters are generally driven by the proton
gradient created by the V-ATPase. Some transporters import macro-
molecules into the lumen to promote their degradation. Membrane
fusion and ﬁssion events are required during lysosomal biogenesis orll rights reserved.for the interaction of lysosomes with their target organelles, i.e.,
endosomes, autophagosomes, phagosomes and plasma membrane
[3]. These membrane trafﬁc events are controlled by complex protein
machineries. Finally, before fusing with their target organelles,
lysosomes move along microtubules, a process which requires the
recruitment of molecular motors to their membrane.
Among the ∼50 known lysosomal storage diseases, a few are
caused by lysosomal membrane protein dysfunction (Table 1). This
number may increase in the future with a better characterization of
the lysosomal membrane proteome [4,5]. Except for mucopolysac-
charidosis type IIIC which is caused by mutations of an enzyme using
cytosolic acetyl-coenzyme A to acetylate intralysosomal α-glucosa-
mine residues [6,7], all lysosomal membrane diseases listed in Table 1
are primarily caused by nonenzymatic defects.
This review focuses on the molecular function and dysfunction of
lysosomal transporters and channels as well as the molecular
pathophysiology of Danon disease. Although the neuronal ceroid
lipofuscinosis subtypes associated with CLN7 and CLN3 defects may
Table 1
Genetic and molecular features of lysosomal storage diseases caused by defects in lysosomal membrane proteins
Human disease OMIM # Inheritance Causative gene,
locus
Protein name
(aliases)
Protein size, # of
transmembrane
helices (TM)
Molecular function Substrates Animal models Other genetic
models
Cystinosis 219800 (infantile) Autosomal recessive CTNS, 17p13 [17] Cystinosin 367 aa; 7 TM H+/amino acid
symport [19]
L-cystine Mouse KO [23] S. cerevisiae
(ERS1) [155]219900 (juvenile)
219750 (adult,
nonnephropathic)
Salla disease 604369 Autosomal recessive SLC17A5,
6q14–q15 [42]
Sialin 495 aa; 12 TM H+/sugar symport [47,48],
vesicular amino acid
import [57]
Sialic acids, acidic hexoses
(organelle export)
Aspartate, glutamate
(import)
None
Infantile sialic acid
storage disorder
269920
Cobalamin F-type
disease
277380 Autosomal recessive LMBRD1, 6q13 [171] LMBD1 540 aa; 9 TM Membrane transport
(predicted) [64]
Cobalamin (predicted) None
Neuronal ceroid
lipofuscinosis, late
infantile variant
610951 Autosomal recessive MFSD8,
4q28.1–q28.2 [10]
CLN7 518 aa; 12 TM Membrane transport
(predicted)
Unknown None
Neuronal ceroid
lipofuscinosis,
juvenile form
204200 Autosomal recessive CLN3, 16p12.1 [156] CLN3 (Battenin) 438 aa; 6 TM Unknown Unknown Mouse KO and KI
[157–159]
S. cerevisiae
(BTN1) [160],
S. pombe (BTN1)
[161]
Malignant infantile
osteopetrosis
611490 Autosomal recessive CLCN7, 16p13 [83] ClC-7 805 aa; 18 TMa H+/anion antiport [87] Cl− Mouse KO [80,83]
259700 Autosomal recessive OSTM1, 6q21 [82] OSTM1 338 aa; 1 TM ClC-7 ancillary subunit
[79]
N.A. Mouse grey-lethal
line [82]
Mucolipidosis IV 252650 Autosomal recessive MCOLN1,
19p13.3–p13.2
[98–100]
TRPML1
(mucolipin-1,
MLN1)
580 aa; 6 TM Cation channel [123–126] Na+, K+, Ca2+; Fe2+; H+? Mouse KO [101],
Drosophila [121],
C. elegans (cup-5)
[112,113]
Mucopolysaccharidosis
Type IIIC (Sanﬁlippo
syndrome C)
252930 Autosomal recessive HGSNAT, 8p11.1 [6,7] HGSNAT
(TMEM76)
663 aa; 11 TM Acetyl-transferase [75] Alpha-glucosamine
residues of heparan
sulphate (lumen)+acetyl-
CoA (cytosol)
None
Niemann–Pick type C 257220 Autosomal recessive NPC1,
18q11–q12 [162]
NPC1 1278 aa; 11 TM Unknown (binds sterols)
[163, 164]
Unknown Mouse C57BLKS/J
spm and BALB/c npcnih
lines [165], cat [166],
Drosophila [167],
C. elegans [168]
S. cerevisiae
[169]
Danon disease 300257 X-linked dominant LAMP2, Xq24 [141] LAMP2 (LAMPB,
LGP110)
410 aa; 1 TM Lysosome fusion and
motility [151], Chaperone-
mediated autophagy [148]
N.A. Mouse KO [143]
Abbreviations: aa, amino acids; KI, knock-in; KO, knock-out; N.A., not applicable.
a Some helices partially span the membrane.
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this topic is covered in another review of this special issue [11]. The
complex issue of the pathogenesis of Niemann–Pick type C1 disease
[12,13] and the elusive function of NPC1 are not addressed here owing
to space limitations.
2. Lysosomal storage diseases caused by defective
small-metabolite export
2.1. Cystinosis
Cystinosis, which is characterized by lysosomal accumulation of
cystine in many tissues, was the ﬁrst known storage disorder caused
by defective metabolite export from the lysosome [14,15]. Three
clinical forms have been described according to the severity and age of
onset of symptoms [16]. The most severe form, infantile cystinosis
(OMIM 219800), appears in the ﬁrst year of life as a renal tubulopathy
(Fanconi syndrome) which eventually progresses to glomerular
damage and renal failure at ∼10 years of age if left untreated.
Photophobia, caused by the presence of cystine crystals in the cornea,
is another hallmark of cystinosis. The widespread accumulation of
cystine leads to diverse manifestations including growth retardation,
diabetes mellitus, hypothyroidism, myopathy and neurological dete-
rioration. Juvenile cystinosis (OMIM 219900) appears in adolescence
with similar, albeit milder, symptoms and a slower clinical course.
Adult cystinosis (OMIM 219750) patients only present with ocular
manifestations. Cystinosis is treated by oral doses and eyedrops of
cysteamine, a drug which depletes cystine from lysosomes by
exporting a cysteine–cysteamine conjugate through another non-
affected transporter [16].
2.1.1. Molecular properties of cystinosin
Cystinosis is caused by inherited defects of a seven transmembrane
domain (TM) protein named cystinosin [17]. The most common
mutation is a 57-kb deletion which removes the promoter region and
the ﬁrst ten exon of the CTNS gene [16,17]. Cystinosin localizes to
lysosomes and late endosomes by virtue of two targeting signals: a
classical tyrosine-based sortingmotif present in the C-terminal tail and
an atypical signal present in the intracellular loop connecting the ﬁfth
and sixth TM (Fig. 1) [18]. Deletion of either signal signiﬁcantly
misroutes cystinosin to the plasma membrane while partially preser-
ving lysosomal localization; however, when both signals are inacti-
vated, cystinosin is fully misrouted to the cell surface. Themechanistic
signiﬁcance of the internal signal is unclear as alanine scanning
mutagenesis could not identify critical residues in its sequence.
The direct accessibility of these sorting mutants at the cell surface
was exploited to set up awhole-cell functional assay of cystinosin [19].
An advantage of this approach, in which lysosomal efﬂux is replaced
by a topologically equivalent whole-cell uptake, is that it requires low
amounts of transfected cells in contrast with measurements
performed on puriﬁed lysosomes — see Ref. [2]. Cells expressing the
tyrosine motif mutant acquired the capacity to take up cystine from
the extracellularmediumwhen this medium (topologically equivalent
to the lysosomal lumen)was acidiﬁed [19]. Uptakewas inhibited by an
H+ ionophore in agreement with an H+ symport mechanism (H+/
cystine cotransport) actively driving cystine out of the lysosome. The
afﬁnity for cystine and the substrate selectivity were similar to that
previously observed on puriﬁed lysosomes [20], suggesting that the
functional properties of cystinosin are not altered by its expression at
an ectopic membrane [19].
The whole-cell transport assay was thus used in a subsequent
study to characterize the functional impact of pathogenic mutations
[21]. Thirty one missense mutations or in-frame deletions and
insertions associatedwith diverse clinical phenotypeswere examined.
None of them abolished lysosomal localization of cystinosin suggest-
ing that impaired transport may be the second most frequent cause ofpathogenicity after the 57-kb deletion. In agreement with this view,
transport activity tended to correlate with the clinical phenotype
when these 31 mutations were introduced into the tyrosine motif-
lacking construct. Transport was abolished in N80% of the mutations
associated to infantile cystinosis, while 60% of the mutations
associated to juvenile cystinosis and the missense mutation (G197R)
associated to ocular cystinosis strongly inhibited, but did not abolish,
cystine transport [21]. Some of the mutations which did not follow
this tendency could be explained by the existence of splicing defects
or polymorphisms. However, seven other ‘discrepancies’ remained
unexplained, suggesting that some functional aspects may not be
recapitulated in the whole-cell assay or that environmental factors or
the genetic background may contribute to the clinical variability [21].
A recent study has identiﬁed a splicing isoform of cystinosin in
human kidney which differs from ‘canonical’ cystinosin in its C-
terminal tail [22]. The variant tail is longer and it lacks the tyrosine-
based sorting motif. This novel isoform is expressed at the plasma
membrane in addition to lysosomes and it translocates cystine across
membranes. However, its functional signiﬁcance has not yet been
investigated in detail.
2.1.2. Cellular impact of cystine storage
The mechanism linking lysosomal cystine storage to pathological
manifestations, in particular to the prominent proximal tubular
defects, remains unclear. Disruption of the Ctns gene in mice induces
cystine storage in many tissues and it recapitulates the ocular
anomalies of cystinosis; however, cystinosin-lacking mice did not
show signs of tubulopathy or renal failure [23]. Earlier experiments on
dissected renal proximal tubules had implicated mitochondrial ATP
synthesis in cystinosis based on the fact that cystine dimethyl ester, a
drug used to load artiﬁcially lysosomes with cystine, inhibits tubular
transport by depleting ATP levels [24]. However, this effect has been
recently attributed to a toxic effect of the dimethyl ester which is
absent from cystinotic cells [25].
As protein reabsorption in renal proximal tubules depends on
endocytosis of the multiligand receptors cubilin and megalin [26], the
distribution of these receptors was examined in cystinotic kidney
tissue [27]. However, normal levels of both cubilin and megalin were
found at the brush border membrane of cystinotic renal proximal
tubules. Moreover, the intracellular immunohistochemical staining of
their protein ligands was normal or even increased, suggesting that
tubular protein reabsorption is impaired at a step downstream of
cubulin- and megalin-dependent endocytosis in cystinosis [27].
Other pathophysiological studies have focused on general cellular
defects in ﬁbroblasts and renal proximal tubular cells derived from
cystinotic patients or knock-out mice. It is generally assumed that
cystine is not toxic inside the lysosome, thus shifting attention to
consequences of cystine storage on non-lysosomal compartments.
Two types of cellular dysfunctions have been documented thus far. On
one hand, several groups reported a decreased level of glutathione
[28–30], or an inverse correlation between cystine and glutathione
levels [31], in cystinotic cells. The sequestration of cystine in
lysosomes may thus limit the cytosolic availability of cysteine and,
consequently, glutathione synthesis, thereby increasing the suscept-
ibility of cystinotic cells to oxidative stress.
On the other hand, cystinotic cells have been found to be more
sensitive to apoptosis inducers [32] and this effect has been, at least
partly, linked to cysteinylation, and activation, of the pro-apoptotic
kinase protein kinase Cδ [33]. Pulse-chase labelling with 35S-labelled
cystine dimethyl ester showed that the cysteinyl moiety conjugated to
protein kinase Cδ derives from lysosomal cystine. Since lysosomal
membrane permeabilization has been implicated in caspase-inde-
pendent cell death [34], it has been suggested that cysteinylation of
protein kinase Cδ and, presumably, other cytosolic proteins occurs
during the release of a ‘bolus’ of cystine from permeabilized cystinotic
lysosomes [33,35].
Fig. 1. Topological models of the lysosomal membrane proteins covered in this review. Putative models based on sequence analysis are depicted, except that of ClC-7 which derives
from the 3D structure of a bacterial homologue [170]. Lysosomal sorting motives (critical residues shown in italic characters), splicing isoforms and pathogenic mutations (framed)
discussed in the text are indicated. Sialin pathogenic mutations are displayed in different colors depending on the associated clinical phenotype: blue, association with Salla or Salla-
like phenotypes; red, ISSD; red and blue, clinically heterozygous mutation; black, clinical association uncertain (second allele of a splicing mutation).
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Two lysosomal storage diseases are caused by defective free sialic
acid export from the lysosome: infantile sialic acid storage disorder
(ISSD, OMIM 269920) and Salla disease (OMIM 604369) [36]. ISSDpresents with facial dysmorphism, hepatosplenomegaly, severe motor
retardation, failure to thrive and early death (b2 years or in utero).
Salla disease is a progressive, neurological disease presenting with
hypotonia, ataxia and psychomotor retardation. Somatic ﬁndings are
rare and lifespan is almost normal. An intermediate clinical form,
640 R. Ruivo et al. / Biochimica et Biophysica Acta 1793 (2009) 636–649which is similar to Salla disease but displays a faster clinical course,
has also been described [37,38]. A central hypomyelination with
thinning of the corpus callosum and cerebellar atrophy is found in
both Salla disease and ISSD [38–41]. There is no speciﬁc therapy.
2.2.1. Sialic acid transport dysfunctions associated with ISSD and Salla
disease
Both diseases are caused by mutations in the SLC17A5 gene which
encodes a membrane transporter, named sialin, sharing homology
with synaptic vesicle glutamate transporters [42,43]. Salla disease is
characterized by missense mutation (R39C) of an arginine residue
conserved in the whole SLC17 family [37,42]. Most patients are
homozygous for this mutation, but compound heterozygotes are also
observed and generally display an increased severity. On the other
hand, ISSD patients show diverse mutations including large deletions
and a small in-frame deletion (ΔSSLRN), as well as nonsense and
missense mutations. However, the R39C allele has never been
observed in those patients [37].
This genotype/phenotype relationship suggested that the R39C
mutation would have a milder effect on sialin function than ISSD-
associated mutations. However, earlier ﬂux measurements on lyso-
somes isolated from patients' ﬁbroblasts could not detect sialic acid
transport in both Salla and ISSD lysosomes [44–46]. The identiﬁcation
of sialin allowed re-examining the molecular pathogenesis of these
diseases by providing a novel, more sensitive transport assay based on
the recombinant protein [47,48].
Immunoﬂuorescence microscopy showed that recombinant sialin
localizes to lysosomes and late endosomes in transfected cell lines
[47,49]. Another study reported only partial colocalization with late
endosomes and lysosomes [48]. However, it was based on a construct
bearing a missense mutation (N41G) in the ﬁrst TM domain which
may alter the intracellular distribution. Site-directed mutagenesis
studies showed that a dileucine-based sorting motif present in the N-
terminal tail (Fig. 1) is essential for this lysosomal localization. Sialin is
misrouted to the plasmamembrane when the critical leucine residues
of this motif are mutated [47,48].
A whole-cell transport assay similar to that initially developed for
cystinosin [19] was thus used to characterize the transport activity of
sialin [47,48]. Cells expressing the dileucine-lacking construct at the
plasma membrane accumulated sialic acid at low, but not neutral,
extracellular pH. In agreement with previous ﬁndings on rat and
human lysosomes [46,50], sialic acid transport required a downhill
proton gradient and was inhibited by acidic monosaccharides and
monocarboxylates such as pyruvate and lactate, but not by neutral
monosaccharides or amino acids [47]. Therefore, the expression of
sialin at an ectopic membrane did not alter its transport properties.
The whole-cell transport assay was then used to investigate the
molecular effect of mutations associated with different forms of
sialic storage disorder [47,48,51,52]. All mutations associated with
ISSD had severe effects on either function or expression of
recombinant sialin. One missense mutation (G371V) triggered
endoplasmic reticulum retention and degradation. Four other mis-
sense mutations and a short in-frame deletion abolished transport
while partially (R57C, G127E, H183R, ΔSSLRN) or fully (P334R)
preserving lysosomal localization.
By contrast, the Salla founder mutation R39C partially preserved
both lysosomal localization and sialic acid transport, with a ∼15%
residual transport in the whole-cell assay [47,48]. Interestingly,
another mutation (K136E) found in homozygous state in a patient
with a ‘severe Salla’ phenotype (characterized by more severe and
earlier onset neurological symptoms without hepatosplenomegaly or
skeletal changes) [38] had similar effects [47,48], thus suggesting that
somatic signs are caused by a full blockade of lysosomal sialic acid
export. It should be mentioned that, by contrast, another mutation
(G409E) found in a heterozygous Salla-like patient [53] abolished
transport [51,52]. However, the moderate severity of her phenotypemay be caused by a variable expression of the splicing defect of the
second allele from one cell type to another [52,53].
A third type of mutation (G328E) was found in homozygous state
in a clinically heterogeneous family with presentations ranging from
typical ISSD to a muchmilder Salla-like phenotype [54]. This mutation
did not alter lysosomal localization. Unexpectedly, it abolished sialic
acid transport in the whole-cell assay [51,52], thus suggesting that the
clinical variability observed in this family may arise from a protective
effect of environmental or genetic factors [52].
2.2.2. Non-lysosomal functions of sialin
As Salla disease is essentially a neurological disease, several studies
have focused on the role of sialin in central nervous system.
2.2.2.1. Presence of sialin in axons. Two studies have examined the
distribution of sialin in mouse brain [55,56]. The distribution pattern
as well as immunoblotting analysis of primary cultures showed that
sialin is more abundant in neurons than glial cells [55]. Immunohis-
tochemical analysis of brain sections showed that sialin predominates
in cerebral and cerebellar cortices, hippocampus, striatum and some
midbrain nuclei of adult mouse brain [55,56]. Both studies reported a
clear immunolabelling of neuronal cell bodies such as those of
hippocampal pyramidal cells, cerebellar Purkinje cells ormitral cells of
the olfactory bulb. However, they diverged for the distribution of sialin
in other neuronal compartments. Whereas Yarovaya et al. [56]
reported a predominant labelling of the neuropil in many brain
regions without signiﬁcant immunoreactivity of the white matter, a
strong labelling of axonal tracts was observed by Aula et al. [55]. This
discrepancymay arise from the fact that older brains were analyzed in
the second study (up to 6 months vs. 1 month).
At subcellular level, endogenous or transfected sialin was found in
vesicular structures present in cell bodies, but also along axons and in
growth cones of cultured neurons [55]. In cell bodies, sialin puncta
were reported to be distinct from LAMP1-laden lysosomes [55], in
contrast to what occurs in nonneuronal cells [47,49], thus suggesting
that sialin may play predominantly a nonlysosomal function in brain
[55]. However, our own observations did not support this conclusion;
we conﬁrmed the presence of sialin in axons, but the most intense
staining was found in neuronal cell bodies and it colocalized with
LAMP1 puncta (C.S. & B.G, unpublished data). Another discrepancy
regards the identity of the axonal pool of sialin. Aula et al. [55]
reported that sialin mostly localizes to the plasmamembrane in axons
of cultured hippocampal neurons, without signiﬁcant colocalization
with the synaptic vesicle marker synaptophysin. However, another
study found sialin on synaptophysin-positive synaptic vesicles
accumulating in axonal boutons of hippocampal neurons [57].
2.2.2.2. Unexpected role of sialin in aspartatergic neurotransmission. The
presence of sialin in hippocampal synaptic vesicles prompted
Moriyama et al. [57] to examine whether it participates in neuro-
transmission as do its VGLUT paralogues at glutamatergic synapses.
Strikingly, they showed that sialin is a bifunctional transporter able to
import aspartate and glutamate into acidic organelles in addition to its
well-established sialic acid export activity. This additional amino acid
transport activity is supported by ﬂux studies on proteoliposomes
containing puriﬁed sialin and by the fact that siRNA-mediated
silencing of endogenous sialin in pinealocytes decreases their capacity
to release aspartate or glutamate. It was thus concluded that sialin
represents the long-sought vesicular neurotransmitter transporter
involved in aspartatergic neurotransmission [57].
A surprising feature of this bifunctional behaviour is that the two
transport activities appear independent of each other. Indeed,
aspartate and glutamate, on one hand, and sialic acid, on the other
hand, do not compete with each other [47,50,57]. Moreover, the two
activities show differential sensitivity to inhibitors and pathogenic
mutations. For instance, Evans blue and the false transmitter D,L-
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but not sialic acid transport. The Salla mutation R39C abolishes
aspartate and glutamate uptake –while partially preserving sialic acid
transport as mentioned above – whereas the ISSD-associated muta-
tion H183R abolishes sialic acid transport while preserving amino acid
uptake [57]. Sialic acids and acidic amino acids may thus use distinct
transport pathways or distinct binding sites along the same transport
pathway in the sialin structure. A similar coexistence of two
independent transport mechanisms has been reported for VGLUT
proteins with respect to glutamate, on one hand, and phosphate, on
the other hand [58].
2.2.3. Putative pathomechanisms of Salla disease
The association of a non-lethal, neurological phenotype with
residual sialic acid transport [47,48] led us to propose that sialin may
be rate-limiting for speciﬁc central nervous system processes in Salla
disease [47]. In principle, impaired lysosomal export of sialic acid may
affect patient's cells in two ways. On one hand, sialic acid accumula-
tion in the lysosome may interfere with some lysosomal enzymes. For
instance, neuraminic acid is a competitive inhibitor of lysosomal
neuraminidase [59]. The occurrence of such inhibition in vivo is
supported by the report of a moderate increase of soluble sialylated
conjugates in liver and skin ﬁbroblasts from a Salla patient [60]. The
accumulation of labelled GM2 ganglioside in Salla ﬁbroblasts after
pulse-chase application of radioactive GM1 [61] also suggests that β-
hexosaminidase A might be inhibited by the lysosomal accumulation
of glucuronic acid.
On the other hand, the cytosolic compartment should also be
affected since mutations R39C and K136E decrease the transport
capacity (Vmax) of sialin, thus implying that the build-up of a high
sialic acid concentration in the lysosome cannot restore a normal level
of lysosomal efﬂux [47]. This effect should limit the availability of sialic
acid in the cytosol and decrease the level of cell surface sialylation in
cells with a high demand for sialoglycoconjugate synthesis. As
gangliosides are especially abundant in the brain, this hypothetical
mechanism might explain the higher vulnerability of the nervous
system in Salla disease. These considerations and the fact that mice
lacking myelin-associated glycoprotein or their cognate complex
ganglioside ligands show selective CNS dysmyelination [62,63] led
us to propose that brain ganglioside hyposialylation and a consecutive
impaired axoglial interaction might play a central role in Salla disease
pathogenesis [47].
Finally, the recent discovery that sialin has an additional function
in neurotransmitter release and the fact that its aspartate uptake
activity is abolished by the mutation R39C have led to the proposal
that impaired aspartatergic neurotransmission may contribute to
some neurological symptoms of Salla disease [57]. Further investiga-
tion on an animal model is required to examine these diverse
hypotheses.
2.3. Defective cellular entry of a nutrient in cobalamin F-type disease
In addition to their role in the reuse of lysosomal catabolites,
lysosomal transporters contribute to cellular nutrition by exporting to
the cytosol nutrients taken up by endocytosis [2]. Such a role is
illustrated in a subtype of inherited cobalamin metabolism disease
known as cobalamin F-type disease (cblF, OMIM 277380) [64].
Cobalamin, also known as vitamin B12, is used in mammalian cells
as methylcobalamin and adenosylcobalamin cofactors required for the
methylation of homocysteine to methionine in the cytosol and for the
conversion of methylmalonyl coenzyme A to succinyl coenzyme A in
mitochondria, respectively [65]. Human genetic defects in intestinal
absorption, blood transport or intracellular metabolism of cobalamin
result in megaloblastic anaemia and failure to thrive in children, with
severe neurological disturbances if left untreated by high doses of
cobalamin. In the case of intracellular defects, nine complementationgroups have been identiﬁed based on cell fusion experiments. In the F-
type complementation group, cobalamin is not converted into enzyme
cofactors, thus resulting in combined accumulation of homocysteine
and methylmalonic acid which is characteristic of ‘upstream’
cobalamin metabolism defects [65]. In agreement with this clinical
picture, biochemical and ultrastructural analyses of cobalamin F
ﬁbroblasts have shown that endocytosis of transcobalamin II-bound
cobalamin and lysosomal degradation of transcobalamin II are normal
in these cells, but free cobalamin accumulates in the lysosome [64,66].
This disease has thus been associated with defective cobalamin export
from the lysosome. A cobalamin transport activity has been
characterized in rat liver lysosomes [67], but its molecular identity
remains unknown. It may be mentioned that, in contrast to cystinosis
and sialic acid storage disorder, cblF lysosomes do not display
abnormal morphology on examination by electron microscopy
[64,67]. This may be related to the low abundance of cobalamin as
compared to amino acids or sugars.
3. A hybrid enzyme/transporter protein is defective in Sanﬁlippo
type C syndrome
Mucopolysaccharidosis type III, also named Sanﬁlippo syndrome
(OMIM 252930), is caused by defective lysosomal degradation of
heparan sulphate. Patients presents with neuropsychiatric signs
(chaotic behaviour, sleep disturbances) and progressive psychomotor
deterioration with mild somatic signs and premature death in the 3rd
or 4th decade [68]. Four genetic subtypes have been identiﬁed. In the
type C syndrome, lysosomes are defective for a transmembrane
enzyme which catalyzes the N-acetylation of terminal α-glucosamine
residues from heparin and heparan sulphate chains, a step required
for their subsequent cleavage byα-N-acetylglucosaminidase [69]. The
defective enzyme, named HGSNAT (for heparin acetyl-CoA:α-gluco
saminide N-acetyltransferase) has been recently identiﬁed by com-
bined genetic and biochemical or proteomic approaches [6,7]. It
encodes a 663-amino acid protein harbouring 11 TM with a large,
luminal N-terminal domain and a short, cytosolic C-terminal tail (Fig.
1). Recombinant HGSNAT localizes to lysosomes and late endosomes
in transfected cells and it rescues the enzymatic defect of Sanﬁlippo
type C ﬁbroblasts [6,7].
Interestingly, early biochemical studies have shown that this
protein acts both as an enzyme and a transport protein since it uses
cytosolic acetyl-coenzyme A for the acetylation of luminal α-
glucosamine residues [70,71]. The mechanism of this transmembrane
acetylation is debated as some studies support a transfer of the acetyl
group in two steps through an acetylated enzyme intermediate
[72,73], whereas other evidence such as the requirement of free
coenzyme A for the ‘reverse’ acetylation of α-glucosamine by α-N-
acetylglucosamine suggests a single transfer step within a ternary
HGSNAT:coenzyme-A:N-acetylglucosamine complex [74]. The former
view is also supported by genetic evidence indicating that pathogenic
mutations affect either the ﬁrst or the second step of acetyl transfer
[75]. Further studies on recombinant HGSNAT are needed to clarify
this issue.
4. Diseases caused by defective ion ﬂow across the
lysosomal membrane
4.1. A proton/chloride transporter defect underpins neurodegenerative
forms of osteopetrosis
Osteopetrosis is a genetically and clinically heterogeneous group of
osteoclast diseases [76]. Bone resorption is impaired, resulting in bone
fragility, severe haematological failures caused by reduced bone
cavities and impaired haematopoiesis, and blindness and deafness
due to compression of cranial nerves. Two severe forms of osteope-
trosis, OPTB1 and OPTB4 (OMIM 259700 and 611490, respectively),
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to lysosomal storage [77–81]. They have an autosomal recessive
inheritance and are caused by loss-of-function mutations in the genes
encoding the lysosomal ClC protein ClC-7 and its monotopic accessory
protein Ostm1 (Fig. 1) [78,81–83]. It should be mentioned that
dominant-negativemutations of ClC-7 induce an autosomal dominant
form osteopetrosis, known as Albers–Schönberg disease (OMIM
166600), but this disease is apparently not associated with neurolo-
gical symptoms [76,78,84].
4.1.1. Molecular functions of ClC-7 and Ostm1
ClC proteins are chloride channels and transporters involved in the
regulation of plasma membrane excitability, transepithelial transport
and acidiﬁcation of intracellular compartments [85]. The latter
function is primarily achieved by the V-Type H+-ATPase. However,
this electrogenic enzyme requires an electrical shunt to acidify
signiﬁcantly the organelle lumen. Otherwise, the proton-motive
force would be entirely converted into a membrane potential that
prevents further proton pumping. In endosomes, this electrical shunt
is provided by the endosomal chloride transporters ClC-3 and ClC-5
[85]. Therefore, the presence of ClC-7 in the lysosomal membrane and
in the osteoclast rufﬂed border suggested that it may fulﬁl a similar
role in these compartments.
ClC-7was anticipated to represent a Cl−/H+exchanger, rather than
a Cl− channel, because its sequence contains a glutamate residue
which is characteristic of the ClC transporter subclass andmay act as a
cytosolic H+ transfer site [86]. However, the lack of signiﬁcant expres-
sion at the plasmamembrane precluded its functional characterization
byelectrophysiological techniques. Graves et al. [87] circumvented this
difﬁculty by performing direct Cl− and H+ ﬂux measurements on
puriﬁed lysosomes. Under conditions of equal Cl− concentrations on
both sides of the lysosomal membrane, application of a pH gradient
actively drove Cl− towards the acidic compartment, thus implying a
Cl−/H+ exchange mechanism. Moreover, elegant ﬂuorescence-based
measurements of Cl− and H+ equilibrium potentials on lysosomes
voltage-clamped at a set of K+ diffusion potentials showed that, in the
absence of ATP, lysosomal Cl− and H+ ﬂuxes are tightly coupledwith a
stoichiometry of 2Cl−:1H+ [87]. An identical ratio had beenpreviously
determined for bacterial [88] and early endosomal [89,90] ClC
transporters, and for the related plant NO3−/H+ exchanger AtCLCa
[91]. The lysosomal Cl−/H+ exchange activity of the lysosomal
membrane was then assigned to ClC-7 based on the fact that partial
siRNA-based silencing of ClC-7 in HeLa cells reduces lysosomal
accumulation of 36Cl− and of an acidotropic ﬂuorescent probe [87]. It
was thus concluded that ClC-7 is a proton/chloride exchanger and that
it acts as voltage shunt required for sustainedH+pumping byHeLa cell
lysosomes [87]. However, the latter conclusion should be taken
cautiously because accurate ratiometric measurements in ﬁbroblasts
and neurons derived from ClC-7-defective mice did not reveal any
alteration of steady-state lysosomal pH [79,80]. Although redistribu-
tion of other ClC isoforms (ClC-3, ClC-6) to Clcn7−/− lysosomes [92]
may have partially masked a contribution of ClC-7, a likely alternative
explanation is that unidentiﬁed anion transporters of the lysosomal
membrane [2] also contribute to the electrical shunt. In contrast, in the
osteoclast rufﬂed membrane, the shunting activity of ClC-7 plays a
prominent role in V-ATPase-mediated acid secretion [83].
It is unclear why evolution has selected a Cl−/H+ exchange
mechanism, which consumes more ATP than a simple Cl− channel, to
fulﬁl this shunting activity. A ﬁrst possibility is that lysosomal Cl−
accumulation has additional roles, for instance by regulating some
lysosomal enzymes or by driving transport processes [93,94].
Alternatively, since the localization of ClC isoforms to speciﬁc
endocytic organelles suggests that they might be responsible for the
progressive acidiﬁcation of the endocytic pathway, it may be proposed
that the H+ translocation mechanism of ClC transporters is used to
sense and set the internal pH of these organelles.Ostm1 is a highly glycosylated single TM protein which selectively
associates with ClC-7, but not other ClC isoforms, and reaches
lysosomes through this association [79]. The Ostm1/ClC-7 complex
is required for protein stability since ClC-7 levels are dramatically
reduced in grey-lethal mice, which lack Ostm1 [82], and, conversely,
Ostm1 levels are reduced in Clcn7−/−mice [79]. This effect explains the
high phenotypic similarity of grey-lethal andClcn7−/−mice [79,80,83].
4.1.2. Molecular pathogenesis of neurodegenerative osteopetrosis
Disruption of Ostm1 and Clcn7 genes in mice causes osteopetrosis
and a neurodegenerative phenotype associated with lysosomal
storage [79,80,83]. The osteopetrotic condition seems to be directly
related to the electrical shunt role of ClC-7 at the osteoclast rufﬂed
membrane since, when ClC-7 is absent or strongly reduced (Ostm1-
defective cells), the bone resorption lacuna is not acidiﬁed despite the
presence of V-ATPase at the rufﬂed membrane [79,83]. This impaired
acidiﬁcation in turn prevents bone resorption [83] because a low pH is
required to dissolve bone hydroxyapatite crystals and to stimulate
extracellular degradation of the organic matrix by cathepsins [76,95].
On the other hand, the molecular physiopathology of neurode-
generative symptoms associated with ClC-7 or Ostm1 dysfunction is
less clear. Histological analysis of Clcn7−/− and grey-lethal mice
revealed a massive loss of hippocampal pyramidal neurons, cerebellar
Purkinje cells and photoreceptors associated with lysosomal storage
features similar to those of neuronal ceroid lipofuscinosis [79,80]. In
particular, lysosomes from neurons and other cells accumulate an
osmiophilic material containing the subunit c of mitochondrial ATP-
synthase. However, as already mentioned, lysosomal pH was not
altered in cultured Clcn7−/− and grey-lethal neurons [79,80]. The
lysosomal dysfunction underlying neurodegenerative osteopetrosis
may thus involve more speciﬁc, unknown aspects of ClC-7 function.
4.2. Mucolipidosis type IV, a lysosomal channelopathy leading to
lipid storage
Mucolipidosis IV (MLIV; OMIM #252650) is an autosomal
recessive inherited disorder characterized by neurologic and ophthal-
mologic signs associated with lipid storage in lysosomes [96,97]. It
predominantly affects people of Ashkenazi Jewish origin (over 80%),
with an estimated frequency of 1/40,000 and heterozygote frequency
of 1/100. Most patients show psychomotor retardation and ophthal-
mologic abnormalities, including corneal clouding and retinal degen-
eration, associated with impaired secretion of gastric acid by stomach
parietal cells (achlorhydria) and an increase in blood gastrin levels.
The symptoms manifest early in life and progress slowly with a steady
state for two to three decades. Electron microscopy of diverse cell
types show large vacuoles, probably late endosomes or lysosomes,
which store a variety of lipids (phospholipids, gangliosides, neutral
lipids) and mucopolysaccharides forming multiconcentric lamellae
together with granulated, water-soluble substances. There is no
speciﬁc therapy.
4.2.1. Mucolipidosis type IV is caused by mutations of a lysosomal
transient receptor potential (TRP) channel
The causative gene, MCOLN1, localizes to human chromosome
19p13.2–13.3 and is composed of 14 exons [98–100]. It encodes a 580-
amino acid membrane protein named mucolipin-1, MLN1 or TRPML1,
which belongs to the transient receptor potential (TRP) channel
family. Over 16 mutations, including 2 founder mutations which
account for 95% of mutant alleles in Ashkenazi families, have been
identiﬁed in MLIV patients. These founder mutations induce either a
splicing defect with premature translation termination or a deletion of
the ﬁrst seven exons, thus indicating that MLIV is associated with a
loss of TRPML1 function. Interestingly, disruption of the orthologous
Mcoln1 gene in mice nicely recapitulates the neurological, ophthalmic
and gastric defects observed in MLIV patients [101].
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such as heat, mechanical stress, osmolarity or chemicals and act as
sensors of the extracellular or intracellular environment [102]. Some
TRP channels are directly activated by physical or chemical stimuli
whereas others are indirectly activated through second messengers
generated by G protein-coupled (GPCRs) or tyrosine kinase receptors.
TRP polypeptides, including TRPML1, comprise 6 transmembrane
domains (TM) (Fig. 1). The N- and C-terminal tails, which lie in the
cytosol, harbour functional or structural domains which are speciﬁc of
each TRP subfamily. Except for the presence of intracellular sorting
signals [103,104] the cytosolic tails of TRPML1 do not exhibit obvious
functional domains. Like other 6-TM channels, TRP channels are
formed by homo- or hetero-tetramers of TRP polypeptides. The ion-
conducting pore is formed by the TM5 and TM6 helices of the
tetramer, with an ion selectivity ﬁlter created by a ring of TM5/TM6
connecting ‘loops’ in the extracellular half of the channel (Fig.1) [105].
As discussed below, most functional studies conﬁrm that TRPML1
is a cation channel, as other TRP channels, although several important
aspects of the channel function are still unclear. Another important
ﬁnding is that TRPML1 localizes to lysosomes and late endosomes
[103,104,106,107]. The biological relevance of this observation is
strengthened by the presence of two dileucine-type sorting motifs
in the N- and C-terminal tails of TRPML1. Mutation of both motifs is
required to abolish the lysosomal localization, thus resulting in a
misrouting of TRPML1 to the cell surface [103,104]. Interestingly,
neither this double dileucine mutant, nor constructs targeted to the
lysosome but mutated in the pore selectivity ﬁlter are able to rescue
the cellular phenotype of MLIV ﬁbroblasts [103]. This indicates that
TRPML1 function is required in late endosomes or lysosomes.
4.2.2. Intracellular trafﬁcking defects associated with TRPML1
dysfunction
Pulse-chase experiments with a ﬂuorescent analogue of lactosyl-
ceramide (LacCer) revealed a lipid trafﬁcking defect in MLIV cells
[108]. LacCer is endocytosed and trafﬁcs to the lysosome at normal
rate in patient's cells; however, it fails to reach the trans-Golgi
network after 60 min, in contrast to cells from control subjects. MLIV
cells are thus characterized by impaired lipid exit from lysosomes
[103,108–110]. However, this lipid trafﬁcking defect has also been
observed in diverse sphingolipid storage diseases [111], suggesting
that it might be secondary to lipid storage. For instance, the diffusion
of LacCer into membranous inclusions may impair its vesicular
trafﬁcking by decreasing its concentration in the limiting membrane
of the lysosome. This proposal is consistent with the fact that the exit
of LacCer from the lysosome of MLIV cells is delayed rather than
blocked [103].
Additional information on the cellular defects of mucolipidosis
type IV has been provided by genetic studies of a Caenorhabditis
elegans homologue of TRPML1, named CUP-5 (where CUP stands for
‘coelomocyte uptake defective’). Hypomorphic mutations of CUP-5
were selected in a genetic screen for impaired endocytosis in
coelomocytes [112], a group of cells responsible for the clearance of
the body cavity ﬂuid by pinocytosis and lysosomal degradation of its
macromolecule components. In another screen, loss-of-function
mutations causing maternal-effect embryonic lethality were isolated
in a search for suppressors of an anti-apoptotic mutation of a Bcl2-like
gene [113].
CUP-5 localizes to C. elegans lysosomes [113,114]. Fluid-phase
endocytosis is normal or even upregulated in CUP-5-defective
coelomocytes, but endocytosed proteins are not degraded [112]. This
cellular phenotype is not speciﬁc to coelomocytes since the degrada-
tion of soluble or membrane proteins undergoing endocytosis is also
impaired in oocytes and embryos with null alleles of cup-5 [115].
Consequently, large intracellular vacuoles reminiscent of those found
inMLIV cells accumulate in CUP-5-defectiveworms [112,113]. Another
trafﬁcking defect of cup-5 coelomocytes is the lack of segregation ofendocytosed proteins from late-endosome membrane markers at late
stages of endocytosis [114]. In the current view of lysosomes as
dynamic organelles undergoing cycles of fusion and ﬁssionwith target
organelles such as late endosomes [3], this has been interpreted as a
block in lysosome reformation from hybrid organelles by late
endosomal/lysosomal fusion [114]. In agreement with this view, the
vacuoles of cup-5 worms express both late endosomal and lysosomal
markers. It should be mentioned that expression of human TRPML1 in
transgenic worms rescues these endocytosis defects [114].
In addition to these trafﬁcking defects, inactivation of cup-5 also
increases apoptosis in C. elegans embryos [113]. However, this
phenotype is a secondary consequence of the starvation caused by
impaired degradation of endocytosed yolk proteins since it is rescued
when embryos are supplied with a permeant Krebs cycle precursor
[115]. The premature death of cup-5 embryos, which only partially
depends on apoptosis, arises from an overload of lysosomes with
lipids since mutation of an intestinal ABC transporter which pumps
lipids into this organelle (as revealed by a lipophilic stain) rescues this
embryonic lethality [116]. This observation suggests that MLIV might
be partially accessible to substrate reduction therapy.
A mitochondrial fragmentation phenotype has also been reported
in MLIV ﬁbroblasts and in other lysosomal storage diseases [117]. This
phenotype probably reﬂects the general autophagy defect of lysoso-
mal diseases [118] as it can be induced by autophagy inhibitors [117]. A
recent study showed that autophagosome formation is upregulated
and their fusion with late endosomes and lysosomes is delayed in
MLIV ﬁbroblasts [119]. The fragmentation of mitochondria may thus
result from the implication of mitochondria ﬁssion and fusion in the
autophagic clearance of damaged mitochondria [120].
Very recently, a Drosophila MLIV model has been produced which
recapitulates the lysosomal storage and neurodegenerative features of
the human disease [121]. Interestingly, rescue experiments in speciﬁc
cell types of this model revealed an unpexpected contribution of non-
neuronal cells (glia, hemocytes) in disease progression. Although
neurodegeneration primarily arises from an autonomous defect of
trpml neurons, Drosophila TRPML is required in hemocytes and glia to
clear dead neurons from the nervous tissue.
4.2.3. Conﬂicting data on permeability and gating properties of TRPML1
The physiological function of ion channels depends on two
essential properties: their ability to select speciﬁc ion species and
their gating properties. However, no consensus has yet emerged on
these two important functional features of TRPML1.
Several groups reported the existence of a cationic conductance
after incorporating TRMPL1-laden vesicles into planar bilayers
[122,123] or after overexpressing TRPML1 to the plasma membrane
of Xenopus oocytes [124] or HEK 293 cells [107,125,126]. However,
another group failed to record such currents even when the
concentration of TRPML1 at the plasma membrane was strongly
increased by mutating its two dileucine motifs [103]. When a current
was recorded, most studies agreed that TRPML1 is permeable to Na+,
K+ and Ca2+. However there is conﬂicting data on the permeability
to H+ [125,126]. The direction of the cation ﬂow across the lysosomal
membrane under physiological conditions is also debated as some
authors reported the existence of an outward rectiﬁcation [107,125],
which implies a role in the inﬂux of cations into the lysosome,
whereas others observed an inward rectiﬁcation [126] consistent
with an efﬂux of cations from the organelle. During revision of this
review, the latter conclusion has been elegantly conﬁrmed by direct
patch-clamp recording of enlarged, TRPML1-laden lysosomes isolated
from vacuolin-1-treated cells [127]. This novel study will be
discussed further below (Sections 4.2.5 and 4.2.6).
Our knowledge on the signals or conditions which regulate the
opening and closing of TRPML1 is even scarcer. One study performed
in a planar bilayer system reported an inactivation of TRPML1 channel
at low pH [123]. However, the signiﬁcance of this observation is
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the bilayer, which is the side where endosomal vesicles were added
and therefore corresponds to the cytosolic compartment. The same
group reported an inhibition of TRPML1 by increasing Ca2+ up to
90mM in the trans compartment, which is equivalent to the lysosomal
lumen [122]. However, the conclusion that pathogenic mutations had
gain-of-function effects on TRPML1 by relieving this inhibition [122], a
conclusion irreconcilable with – for instance – the phenotype of
TRPML1 knock-out mice [101], questions the physiological relevance
of this Ca2+ effect. In another study, addition of Ca2+ to the cytosolic
side of excised membrane patches stimulated TRPML1 opening [124].
Several groups reported that TRPML1 is cleaved in its ﬁrst luminal
loop during its transit through the trans Golgi network or when it
reaches the lysosome [107,128,129]. The two resulting fragments
remain associated, but channel activity is inactivated by cathepsin B-
mediated cleavage [107], thus raising the possibility that TRPML1
activity is needed at a speciﬁc stage of the biosynthetic or endocytic
pathway. Another layer of complexity stems from the fact that
TRPML1 physically interacts with its paralogues TRPML2 and TRPML3
[129,130]. However, the inﬂuence of this hetero-oligomerization on
channel activity has not yet been explored.
4.2.4. Recent lessons from the TRPML3 activating mutation
varitint-waddler
The TRPML subgroup of TRP channels comprises three proteins in
mammals. Interestingly, several recent and converging studies have
characterized in some detail the activity of TRPML3 [126,131–134]. As
human TRPML3 rescue endocytosis defects as efﬁciently as TRPML1 in
cup-5 mutant worms [114], these channels probably share common
molecular functions and it is worth summarizing here the properties
of TRPML3.
No human disease associated with TRPML3 mutations has been
described, but a semi-dominant missense Trpml3 mutation causing
hearing, vestibular and pigmentation defects has been identiﬁed in
varitint-waddler mice [135]. TRPML3 localizes to lysosomes [132] but
its presence at the plasma membrane of HEK293 cells upon over-
expression allowed functional analysis [126,131–134]. Most studies
have focused on a TRPML3 construct bearing the varitint-waddler
mutation A419P in TM5. Electrophysiological recording aswell as Ca2+
and Na+ ﬂuorescent imaging showed that this mutation strongly
activates the channel activity of TRPML3 and that TRPML3-A419P is
readily permeable to Na+, K+, Ca2+ and, to a lesser extent, Mg2+
without signiﬁcant permeability to H+ [126,132–134]. This non-
selective cationic conductance exhibited an inward rectiﬁcation
(indicating that it promotes cation efﬂux from the lysosome), which
was absent from the wild-type protein under standard conditions.
One study [132] detected an additional outward-rectifying behaviour
but this conductance was much smaller than the inward-rectifying
one. Interestingly, two other studies [131,134] could characterize the
gating properties of the wild-type channel by taking advantage of the
ﬁnding that exposure of the luminal side of wild-type TRPML3 to a Na
+-free solution activates the inward-rectifying conductance to a level
similar to that observed in the A419P mutant. Acidiﬁcation of the
luminal side of wild-type TRPML3 caused a persistent inhibition of the
channel activity, which was reactivated upon exposure to Na+-free
solutions [131]. This inhibition was speciﬁc of the luminal side of the
protein, it occurred with an apparent pKa of ∼6.4 and was assigned to
histidine residues present in the ﬁrst luminal loop of TRPML3. The
varitint-waddler mutation A419P abolished this gating by constitu-
tively activating the channel [131,134].
One study [133] examined the sensitivity of TRPML3-A419P to
osmolarity or mechanical stimuli and found no effect. However, as the
varitint-waddler A419P mutation alters TRPML3 gating, these experi-
ments should be repeated with the wild type protein.
In summary, TRPML3 appears as an endosomal/lysosomal channel
displaying an inward-rectifying, non-selective cationic conductancewhich allows lysosomal efﬂux of divalent cations when the organelle
lumen is neutralized above pH 6.5.
4.2.5. Permeation properties of a varitint-waddler equivalent of TRPML1
Introduction of a mutation (V432P) homologous to the varitint-
waddler allele into TRPML1 activated an inward conductance for
monovalent and divalent cations, with a higher permeability to Ca2+
andMg2+ than TRPML3 [126,133]. No signiﬁcant current was recorded
when all permeant cations were replaced by a large impermeant
cation at low pH, thus ruling out a signiﬁcant permeability of TRPML1
to protons [126]. In a subsequent study [127], the inward-rectifying
cation permeability of TRPML1-V432P was characterized further and
shown to display the following ion selectivity order: Na+NNBa2+N
Mn2+ NFe2+∼ Ca2+∼Mg2+ NNi2+∼ Co2+∼ Cd2+ NZn2+ NNCu2+.
Because of its potential pathophysiological signiﬁcance (see Section
4.2.6), the permeability to Fe2+ was investigated in more detail [127].
Fe2+ permeates TRPML1-V432P through the same conduction pathway
as Na+ and Ca2+ as both divalent ions inhibit the current carried by Na
+. In contrast, TRPML1 is impermeant to Fe3+. The Fe2+ conductance
displays an EC50 of ∼5 mM and it increases when the extracellular
medium (topologically equivalent to the lysosomal lumen) is acidiﬁed
to a pH value of 4.6. These ﬁndings were corroborated by ﬂuorescence-
and 55Fe-based measurement of Fe2+ uptake into TRPML1(V432P)-
overexpressing cells and by direct patch-clamp recording of Fe2+
currents in vacuolin-1-enlarged lysosomes laden with wild-type
TRPML1 or the V432P mutant. Interestingly, this Fe2+ permeability is
a property of TRPML1 and 2, but not of TRPML3 [127].
Taken together, these recent studies show that TRPML1 ensures the
lysosomal efﬂux of monovalent and divalent cations, including Ca2+
and Fe2+ but not Cu2+ nor Fe3+, and that it is active under the
physiological conditions of the lysosomal lumen. However, further
studies on thewild-type protein are needed to characterize extensively
its gating properties since the varitint-waddler mutation alters those
of TRPML3 [131].
4.2.6. Diverging hypotheses on MLIV molecular pathogenesis: Ca2+, H+
and Fe2+ connections
The mechanism linking a lysosomal channel defect to storage and
trafﬁcking defects is highly debated and three diverging pathophy-
siological models have been advanced.
On one hand, the existence of trafﬁcking defects in TRPML1-
defective cells combined with the known Ca2+ selectivity of most TRP
channels prompted several authors to propose that TRPML1would act
by releasing lysosomal Ca2+ stores required to control fusion or ﬁssion
events in the endocytic pathway — see Ref. [136] for review. The
identiﬁcation of these events among the multiple effects of intracel-
lular Ca2+ will probably require time-lapse cell imaging techniques to
monitor this local Ca2+ release and identify its immediate con-
sequences. It is interesting to note that another TRP channel, TRPM7,
has been recently implicated in the fusion of synaptic vesicles with the
plasma membrane [137].
If TRPML1 is gated similarly to TRPML3 [131], this Ca2+ release
would occur onlywhen the organelle lumen is neutralized above pH 6,
that is most probably in an endosomal compartment rather than in
bona ﬁde lysosomes. Alternatively, it is possible that, in vivo,
TRPML1 is gated by other stimuli than luminal pH such as mechanical
and osmotic stresses, or membrane lipids.
On the other hand, Kiselyov and co-workers [110,125] have
challenged this view and proposed a second model resting mainly
on their ﬁnding that TRPML1 appears to regulate lysosomal pH. In
their studies, lysosomes were more acidic in MLIV ﬁbroblasts than in
control cells [125] (however, see Ref. [103,138] for diverging results)
and acute siRNA-mediated silencing of TRPML1 in HeLa cells
decreased lysosomal pH by 1 pH unit [110]. By contrast, they found
no gross alteration of intracellular Ca2+ stores [125]. This hyperaci-
diﬁcation of MLIV lysosomes would in turn inactivate lysosomal
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effect on intracellular trafﬁc [110].
According to these authors, the origin of this hyperacidiﬁcation
would be directly related to the H+ conductance of TRPML1. In other
words, TRPML1 would simply act as a safety valve which releases
protons pumped in excess by the V-ATPase [125]. However, it should
be stressed that the fact that a Cl−/H+ exchange represents the major
proton pathway of HeLa cell lysosomes besides the V-type ATPase (see
Fig. 2b and Supplemental Fig. 2 in Ref. [87]) argues against a
signiﬁcant contribution of TRPML1-mediated H+ conductance to
lysosomal pH homeostasis — see also Ref. [126] for another evidence
against a signiﬁcant H+ permeability of TRPML1. This objection does
not necessarily rule out the metabolic model of MLIV pathogenesis as
TRPML1 might regulate lysosomal pH through Ca2+-activated
processes.
Very recently, a third pathological mechanism has been proposed
based on the iron efﬂux capacity of TRPML1. According to this model
[127], the accumulation of Fe2+ in lysosomes would, on one hand,
reduce the metabolic availability of iron and trigger the anaemic
symptoms of MLIV [96] and, on the other hand, induce neurodegen-
eration by promoting oxidation of protein and lipid substrates of the
lysosome to lipofuscin-like non-degradable materials. This model is
supported by the fact that TRPML1 pathogenic point mutations impair
Fe2+ permeability to a degree which correlates with clinical severity
and by the decreased cytosolic level, and increased lysosomal level, of
iron in MLIV ﬁbroblasts [127]. However, as TRPML3 is able to rescue
cup-5 nematodes [114], but is not permeable to Fe2+ [127], this
mechanism may not account for all effects of TRPML1 dysfunction.
Rescue experiments of cellular and animal models with TRPML1
mutants altered in their ion selectivity properties are needed to
discriminate the contributions of these hypothetical mechanisms and
depict more precisely the ﬁrst steps of the MLIV pathogenic cascade.
5. Danon disease: an autophagy disorder caused by defective
organelle fusion or motility
Danon disease, also named X-linked vacuolar cardiomyopathy and
myopathy (OMIM 300257), is a rare disorder characterized by a
clinical triad of hypertrophic cardiomyopathy, skeletal myopathy and
variable mental retardation [139,140]. It exhibits an X-linked domi-
nant mode of inheritance. Males are thus more frequently and more
severely affected, while females develop milder and later-onset
cardiac symptoms. Retina and liver defects are also observed.
Danon disease is caused by mutations of the gene encoding
lysosome-associated membrane protein-2 (LAMP2), a major protein
of the lysosomal membrane with a single TM, a large, intraluminal,
heavily glycosylated N-terminal domain and a short, cytosolic C-
terminal tail (Fig. 1) [141]. There are three splicing isoforms (LAMP2a,
b and c), which differ in their TM and cytosolic tail encoded by
alternative exon 9. Several LAMP2 mutations resulting in splicing
defects or protein truncation have been identiﬁed. Interestingly, one
patient with a full Danon syndrome had a frameshift mutation in exon
9b, thus suggesting that the disease is mainly associated with a defect
of LAMP2b function [141].
5.1. Autophagy defects in Danon disease
The pathological hallmark of Danon disease is the accumulation of
autophagic vacuoles with sarcolemmal features in myoﬁbers
[140,141]. These vacuoles are enriched in lysosomal enzymes and
autophagy-related markers. However, their limiting membrane also
displays sarcolemmal proteins, such as dystrophin or acetylcholines-
terase, and under electron microscopy the limiting membrane is often
surrounded by a basal lamina [141,142]. The number of vacuoles
increases with age and seems to correlate with the development of
muscle symptoms.Disruption of the lamp2 gene in mice recapitulates the human
disease, albeit with an increased severity and a broader spectrum of
affected tissues [143]. LAMP2-deﬁcient mice showed partial lethality
between postnatal days 20 and 40. Autophagic vacuoles accumulated
in many tissues, especially liver, kidney, pancreas, cardiac and skeletal
muscles, vascular endothelium and neutrophils in both early died and
surviving mice. Studies on cultured hepatocytes derived from this
mouse model revealed that early autophagosomes (containing
undegraded cytosol and organelles) accumulated at a higher ratio
than late autophagosomes in LAMP2-defective cells and that the half-
life of both types of organelles was prolonged [143,144]. Therefore,
autophagosome accumulation results from slower maturation rather
than increased formation. In agreement with this conclusion, the
degradation of long-lived proteins, which proceeds mainly by
autophagy, was decreased and its stimulation by amino acid
deprivation was fully abolished in lamp2y/− hepatocytes[143].
Impaired recycling of 46-kDa mannose 6-phosphate receptors and
partial mistargeting of lysosomal enzymes may also contribute to
decreased proteolysis [144].
5.2. Role of LAMPs in the fusion of lysosomes with target organelles
Several subsequent studies investigated in more detail the
mechanism of this autophagosome maturation defect and, more
generally, the cellular roles of LAMP proteins. LAMP2 shares 37%
amino acid identity with LAMP1, a related protein encoded by another
gene which, with LAMP2, contributes to approximately 50% of all
proteins of the lysosomal membrane. Since a potential functional
redundancy between LAMP1 and LAMP2 may hinder important roles
of LAMPs, the lamp1 gene was also inactivated in mice, individually or
in combination with lamp2 [145,146]. Despite the abundance of
LAMP1 in the lysosomal membrane and in contrast with LAMP2-
deﬁcient mice, LAMP1-deﬁcient mice were normal and their lyso-
somes displayed no morphological or functional alteration [145]. By
contrast, the double knock-out induced a severe synthetic lethality
between embryonic days 14.5 and 16.5, thus showing the existence of
overlapping functions of LAMPs [146]. Autophagic vacuoles accumu-
lated in many tissues and embryonic ﬁbroblasts of double knock-out
mice, with a predominance of early vacuoles suggesting again
impaired autophagosomematuration rather than impaired formation.
However, surprisingly and in contrast with the lamp2y/− hepato-
cytes, proteolysis was not decreased in lamp1−/− lamp2y/−
embryonic ﬁbroblasts, under both amino acid-starved and nonstarved
conditions [146]. Lamp1−/− lamp2y/− ﬁbroblasts also showed an
accumulation of unesteriﬁed cholesterol, which was rescued after
expression of LAMP2a, but not LAMP1.
It should be mentioned that LAMP2a, but not other splicing
isoforms of LAMP2, has been implicated in chaperone-mediated
autophagy (CMA), a process by which cytosolic proteins are directly
translocated into the lysosomal lumen, and degraded, rather than
prealably sequestered into (macro)autophagosomes [147,148]. This
process has several biological functions, including the degradation of
long-lived proteins bearing a CMA-targeting sequence [148] or the
presentation of cytoplasmic antigens by MHC class II molecules [149].
However, unexpectedly, lysosomal degradation of long-lived proteins
was not affected by the double deletion of lamp1 and lamp2 after
inhibition of macroautophagy by 3-methyladenine [146]. A possible
explanation is that a compensatory increase in microautophagy (a
process where proteins to be degraded are captured during the
formation of intralysosomal vesicles) has hindered the blockade of
chaperone-mediated autophagy. Further experiments discriminating
these two processes are needed to clarify this issue.
Interestingly, further analysis of LAMP-deﬁcient cells showed that
LAMPs are involved in the fusion of lysosomes with phagosomes or
autophagosomes [150,151]. In engineered embryonic ﬁbroblasts
where a phagocytotic response has been induced by transfection of
646 R. Ruivo et al. / Biochimica et Biophysica Acta 1793 (2009) 636–649phagocytic receptors, genetic disruption of both LAMPs did not
impaired the capacity to engulf latex beads, but it impaired the
recruitment of the small monomeric GTPase Rab7 by late phagosomes
and their fusionwith lysosomes [151]. As a result, phagosomes lacking
LAMP1 and LAMP2 failed to kill engulfed bacteria [150]. Interestingly,
expression of LAMP2 restored Rab7 phagosomal recruitment more
efﬁciently than LAMP1 [151]. A similar lysosome/phagosome fusion
defect is observed in neutrophils lacking LAMP2 (but not LAMP1)
[152]. This results in selective block of their non-oxidative, lysosome-
based bactericidal capacity but not of their oxidative killing pathway
which leads to a speciﬁc inﬂammatory defect in the oxygen-deprived
environment of the periodontal pocket [152].
Inactivation of LAMP2, but not LAMP1, in HeLa cells and murine
ﬁbroblasts decreased the colocalization of autophagosomal and
lysosomal markers induced by serum deprivation [153]. Therefore,
LAMP2 seems also involved in the fusion of lysosomes with
autophagosomes.
5.3. Organelle motility defects in LAMP-deﬁcient cells
Further analysis of the engineered phagocytes derived from LAMP1
and LAMP2 double-deﬁcient mice also revealed that lysosomes are
more dispersed in the absence of LAMPs and that phagosome and
lysosome migration toward the microtubule-organization center is
delayed [151]. As these dynein-based movements are known to
promote phagosome/lysosome fusion (probably by locally increasing
the density of both organelles) the phagosome maturation defects of
LAMP-deﬁcient cells may be a direct consequence of the motility
defects [151]. Interestingly, a similar centripetal migration of autop-
hagosomes has been implicated in their maturation and fusion with
lysosomes [154]. LAMP2 might thus regulate autophagosome matura-
tion by a similar mechanism.
Note added in proof
The causative gene of cobalamin F type disease has been recently
identiﬁed as LMBRD1. It encodes a lysosomal membrane protein but
its precise molecular has not yet been demonstrated. See Ref. [171]
and Table 1.
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